🇺🇸 FDA
Patent

US 12264366

Genome-based methods for reducing cardiovascular risk

granted A61KA61K2039/505

Quick answer

US patent 12264366 (Genome-based methods for reducing cardiovascular risk) held by REGENERON PHARMACEUTICALS, INC. expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K2039/505